CEL-SCI Corp.’s (NYSE MKT: CVM) body of work with the human
immune system is one of perseverance and a passion for survival despite odds
that would make the vast majority of biotech companies fold their tents and
choose easier endeavors. Faced with trending downturns in the biotech sector,
limited funding, and an arduous clinical trial process connected with the
development of its investigational therapy for advanced primary head and neck
cancer, the company’s mission is now well within sight. CVM’s lead
investigational immunotherapy, Multikine® (Leukocyte Interleukin, Injection),
has been tested in Phase I and II clinical trials, and is now enrolling
patients for a global Phase III trial.
The inception of CVM’s journey began at the Max Planck
Institute in Germany in the late 1970s and has been fueled with science and
research supporting the theory that the immune system is inherently a cancer
fighter. Company founder, Maximilian de Clara, believed strongly that the
immune system is pivotal in fighting this disease, but he did not have the
technology to transition his concept to product. Brushing off discouragement,
Maximilian funded the early Multikine research at the Max Plank Institute in
1978, founded CEL-SCI around the idea of Multikine in 1983, and later took CVM
public.
The company’s mission is to improve the treatment of cancer
and other diseases by utilizing the immune system. CEL-SCI Corp. aims to create
shareholder value by developing unique therapies that address medical needs
that are commonly unmet. The company is dedicated to developing its therapies
using a scientific and data-driven approach.
CVM’s undying spirit aims to be science-based and data
driven – taking no shortcuts on its road to drug development. The company is
steadfast in its ethics and integrity while being economical in its daily
approach to creating shareholder value.
Multikine is the registered trademark under which CEL-SCI
has its investigational therapy. The proprietary name is subject to FDA review
in connection with additional, anticipated regulatory submission for approval
measures. Multikine has not been licensed or approved for sale by the FDA or
any other regulatory agency at this time and its safety or efficacy has not
been established for any use. Further research is required, and early-phase
clinical trial results must be confirmed in Phase III clinical trials, which
are currently underway. CEL-SCI Corporation is headquartered in Vienna,
Virginia.
For more information on this company visit
http://www.cel-sci.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
